文献速递腹部CTMR

LI-RADS CT/MRI 非放射治疗反应评估 2024 版对手术切除肝细胞癌局部复发的检测

LI-RADS CT/MRI Nonradiation Treatment Response Assessment Version 2024 for Detecting Local Recurrence of Surgically Resected Hepatocellular Carcinoma.
PubMed 文献 · AJR Am J Roentgenol · 2026-03-11

回顾性纳入 200 例手术切除肝细胞癌患者,比较 LI-RADS CT/MRI 非放射治疗反应评估 2024 版与核心版 2018 版对手术切缘局部复发的检测。2024 版在 28.0% 患者中检测到局部复发,较 2018 版更早(中位 5.1 个月 vs 12.0 个月)且更小(中位 1.5 cm vs 2.1 cm)。

要点

  • 2024 版将切缘「肿块样强化(任何期相、任何大小)」定义为 LR-TR Viable 即局部复发。
  • 2024 版较 2018 版更早(中位 5.1 个月 vs 12.0 个月)和更小(中位 1.5 cm vs 2.1 cm)检出复发。
  • 2024 版读者间一致性为 substantial(κ=0.71)。

核心结论

  • 2024 版在 28% 患者中检测到局部复发,且较 2018 版更早、更小。

研究设计与样本

  • 回顾性研究,纳入 200 例手术切除肝细胞癌患者(142 男,58 女;中位年龄 67 岁),术后至少 6 个月行肝脏 CT 或 MRI;两名放射科医师独立分别用 2024 版和 2018 版评估手术切缘,第三名医师解决分歧;中位随访 30.5 个月。

关键影像表现/征象

  • 2024 版将手术切缘的 LR-TR Viable 定义为任何期相、任何大小的肿块样强化,即局部复发。
  • 2018 版将手术切缘的 LR-5、LR-M 或 LR-TIV 定义为局部复发。
  • 2024 版判定 LR-TR Viable 的 56 例中,首次术后检查即判定 21 例,直接由 LR-Nonviable 判定(无 intervening LR-TR Equivocal)31 例,LR-TR Equivocal 后判定 4 例。
  • 2024 版判定 LR-TR Viable 时,2018 版对应分类为 LR-3、LR-4、LR-5、LR-M、LR-TIV 者分别为 21、10、18、3、4 例。

诊断标准与关键数值

  • 2024 版:手术切缘 LR-TR Viable(任何期相、任何大小的肿块样强化)定义为局部复发,56 例(28.0%)在中位 5.1 个月、中位观察大小 1.5 cm 时判定。
  • 2018 版:手术切缘 LR-5、LR-M 或 LR-TIV 定义为局部复发,52 例(26.0%)在中位 12.0 个月、中位大小 2.1 cm 时判定(时间 p<.001,大小 p<.001)。
  • 2024 版读者间一致性 κ=0.71(substantial)。
  • LR-3 和 LR-4 观察升级至 LR-5、LR-M 或 LR-TIV 的中位时间分别为 5.1 个月和 3.0 个月。

临床应用与阅片要点

  • 2024 版可用于肝细胞癌切除术后手术切缘评估,较 2018 版更早、更小地检出局部复发。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. LI-RADS CT/MRI Nonradiation Treatment Response Assessment (TRA) version 2024 (v2024) specifies that the updated algorithm may be applied for evaluating the surgical margin after resection of hepatocellular carcinoma (HCC). OBJECTIVE. The purpose of this study was to compare detection of local recurrences after surgical resection of HCC between LI-RADS CT/MRI Nonradiation TRA v2024 and the LI-RADS CT/MRI Core version 2018 (v2018) diagnostic algorithm. METHODS. This retrospective study included patients with surgically resected HCC who underwent at least one liver CT or MRI examination performed at least 6 months postoperatively. Two radiologists independently reviewed all postoperative CT and MRI examinations of included patients in separate sessions, assessing the surgical margin by use of LI-RADS CT/MRI Nonradiation TRA v2024 and LI-RADS CT/MRI Core v2018, respectively; a third radiologist resolved discrepancies. Local recurrence was defined by v2024 as LR-TR Viable (i.e., masslike enhancement at the margin, noted in any phase and of any size) and by v2018 as LR-5, LR-M, or LR-TIV. RESULTS. The study included 200 patients (142 men and 58 women; median age, 67 years) with a median follow-up of 30.5 months. Interreader agreement for v2024 categorization was substantial (κ = 0.71). By v2024, LR-TR Viable at the surgical margin was assigned in 56 patients (28.0%) (on the initial postoperative examination in 21 patients, directly after an LR-Nonviable assignment without an intervening LR-TR Equivocal assignment in 31 patients, and after an LR-TR Equivocal assignment in the remaining four patients); the assignments were made after a median of 5.1 months and at a median observation size of 1.5 cm. By v2018, LR-5, LR-M, or LR-TIV was assigned at the surgical margin in 52 patients (26.0%) after a median of 12.0 months (p < .001) and at a median size of 2.1 cm (p < .001). At the time of the 56 initial LR-TR Viable assignments, the categories assigned for v2018 were LR-3, LR-4, LR-5, LR-M, and LR-TIV in 21, 10, 18, three, and four patients, respectively. Upgrading of LR-3 and LR-4 observations to LR-5, LR-M, or LR-TIV occurred after a median of 5.1 and 3.0 months, respectively. CONCLUSION. v2024 detected local recurrence in 28% of patients at an earlier time and at a smaller size than did v2018. CLINICAL IMPACT. The findings support application of v2024 for surgical margin evaluation after HCC resection.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Chiu SH, Yoon L, Altmayer S, et al. LI-RADS CT/MRI Nonradiation Treatment Response Assessment Version 2024 for Detecting Local Recurrence of Surgically Resected Hepatocellular Carcinoma. AJR Am J Roentgenol. 2026. PMID: 41190834. doi:10.2214/AJR.25.33787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。